查詢結果分析
相關文獻
- EGFR-TKIs用於晚期非小細胞肺癌
- 非小細胞肺癌術前輔助性化學治療的經驗
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
- 非小細胞肺癌的治療
- 晚期非小細胞肺癌之化學治療
- CA405之基因療法合併化學抗癌藥物對肺癌細胞之作用效果評估與機轉的探討(2)
- Treatment of Non-Small-Cell Lung Cancer: The Chinese Experience in a General Teaching Hospital
- erbB基因與非小細胞肺癌的原發抗藥性
- Concurrent 5-Fluorouracil, Leucovorin, Etoposide, Cisplatin and Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
頁籤選單縮合
題名 | EGFR-TKIs用於晚期非小細胞肺癌=Treatment of EGFR-TKIs in Non-Small Cell Lung Cancer |
---|---|
作者 | 彭姿蓉; 李銘嘉; 吳大圩; | 書刊名 | 藥學雜誌 |
卷期 | 31:2=123 2015.06[民104.06] |
頁次 | 頁32-37 |
分類號 | 418.31 |
關鍵詞 | 非小細胞肺癌; 表皮細胞生長因子接收器-酪胺酸激酶抑制劑; Non-small cell cancer; NSCLC; Epidermal growth factor receptor-tyrosine kinase inhibitors; EGFR-TKIs; |
語文 | 中文(Chinese) |
中文摘要 | 肺癌在台灣是主要的癌症死亡原因。約有85%的肺癌為非小細胞肺癌 (non-small cell lung cancer,NSCLC),其常在晚期才被診斷出來,若以傳統第一線化學治療,療 效反應率約僅20%,病人整體存活率之中位數為8-11月。NSCLC 病人約有40-80%會 有表皮細胞生長因子接受器 (epidermal growth factor receptor,EGFR) 過度表現,導致 癌症的快速生長、轉移與抗藥性。如能使用表皮細胞生長因子接收器-酪胺酸激酶抑 制劑 (epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs),則可抑 制肺癌細胞的增生。NSCLC 的 EGFR 有幾種基因型 (如 kinase domain exon 18-21、 T790M) 的變異,使治療肺癌藥品的發展,由可逆性的第一代 EGFR-TKIs (gefitinib、 erlotinib) 進展至不可逆性的第二代 EGFR-TKIs (afatinib),這些藥品的上市讓肺癌有新 的治療選擇。 |
英文摘要 | Lung cancer is the major cause of all cancer-related deaths in Taiwan. Non-small cell cancer (NSCLC), the most common type, comprising 85% of lung cancer is usually diagnosed at advanced stages. The response rate is only 20%, with median survival of 8 to 11 months even if the first line chemotherapy administrated. The epidermal growth factor receptor (EGFR) family members seem to play a critical role in lung tumourigenesis, metastasis, drug resistant and are overexpressed in 40-80% of NSCLC. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) seem to be an effective therapy for inhibiting the growth of cancer cells. Several mutations have been identified in NSCLC, including kinase domain exon 18-21 and T790M. The development of drugs for lung cancer therapy has gone from the first-generation characterized by reversibility of EGFR-TKIs to second-generation as of irreversibility of EGFR-TKIs. And the induction of these drugs has provided new choices for the lung cancer treatment. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。